Yuriy A. Lantsukhay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuriy A. Lantsukhay has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Maria Yu. Konoshenko
Institute of Chemical Biology and Fundamental Medicine
2 shared publications - Olga Evgenievna Bryzgunova
Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, 630090 Novosibirsk, Russia
2 shared publications - Pavel Petrovich Laktionov
Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, 630090 Novosibirsk, Russia
2 shared publications - Sergey E. Krasilnikov
Federal Research Center for Fundamental and translational medicine
2 shared publications - Antonina Aleksandrovna Ilyushchenko
Research Institute of Pulmonology of the Federal Medical-Biological Agency of the Russian Federation, Orekhoviy Boulevard 28, Moscow 115682, Russia
1 shared publication - Ekaterina A. Murina
Institute of Chemical Biology and Fundamental Medicine
1 shared publication
Latest Publications
- Open Access
- 8 January 2026
- Published by ECO-Vector LLC (Publications) in Journal of Clinical Practice
- Vol. 16 (4) , 7-17
MicroRNA from the blood extracellular microvesicles for minimally invasive diagnostics of lung cancer
BACKGROUND: Asymptomatic development and untimely diagnostics of lung cancer are the main reasons of high mortality caused by this disease. The development of tests based on “fluid biopsy”, which analyze circulating nucleic acids in blood, including the microRNA (miRNA) derived from the microvesicles, can be implemented as an effective screening test for lung cancer assuring the timely detection of the disease. AIM: To analyze the relative expression of 17 miRNAs in the microvesicles fraction from blood plasma samples from patients with non-small-cell lung cancer (NSCLC) and healthy donors. METHODS: The blood plasma microvesicles were isolated by aggregation-precipitation. miRNA was then isolated from the obtained blood microvesicles fraction using the glass fiber filters. Using the method of reverse transcription polymerаse chain reaction, an evaluation was carried out for the diagnostic efficiency of previously proposed miRNA pairs. This analysis was also used to select the most effective diagnostic pairs and panels. RESULTS: The obtained data have confirmed the diagnostic efficiency of four miRNA pairs (-31/-125b; -133b/-374a; -133b/-425; -133b/-222). The sensitivity and the specificity of distinguishing NSCLC patients from donors were 79% and 100%, respectively. Further analysis using paired normalization, compiling the regression models and multiple sample generations yielded three independent minimal panels of miRNA pairs, capable of diagnosing NSCLC with 100% accuracy: (1) -19b/-425, -125b/-378a, -205/-660; (2) -324/-374a, -30e/-92a, -125b/-378a; (3) -324/-374a, -125b/-378a, -205/-660. CONCLUSION: The diagnostic performance of the proposed miRNA panel across independent cohorts, along with the observed inter-cohort variability, supports its promising potential for NSCLC screening test development. These data demonstrate the necessity to identify additional multi-purpose miRNA markers and to validate the panel in further independent patient groups. Such research is essential to establish a reliable and timely miRNA-based screening tool for NSCLC.
- 8 January 2026
- Published by ECO-Vector LLC (Publications) in Journal of Clinical Practice
- Vol. 16 (4) , 7-17
Open AccessMicroRNA from the blood extracellular microvesicles for minimally invasive diagnostics of lung cancer
BACKGROUND: Asymptomatic development and untimely diagnostics of lung cancer are the main reasons of high mortality caused by this disease. The development of tests based on “fluid biopsy”, which analyze circulating nucleic acids in blood, including the microRNA (miRNA) derived from the microvesicles, can be implemented as an effective screening test for lung cancer assuring the timely detection of the disease. AIM: To analyze the relative expression of 17 miRNAs in the microvesicles fraction from blood plasma samples from patients with non-small-cell lung cancer (NSCLC) and healthy donors. METHODS: The blood plasma microvesicles were isolated by aggregation-precipitation. miRNA was then isolated from the obtained blood microvesicles fraction using the glass fiber filters. Using the method of reverse transcription polymerаse chain reaction, an evaluation was carried out for the diagnostic efficiency of previously proposed miRNA pairs. This analysis was also used to select the most effective diagnostic pairs and panels. RESULTS: The obtained data have confirmed the diagnostic efficiency of four miRNA pairs (-31/-125b; -133b/-374a; -133b/-425; -133b/-222). The sensitivity and the specificity of distinguishing NSCLC patients from donors were 79% and 100%, respectively. Further analysis using paired normalization, compiling the regression models and multiple sample generations yielded three independent minimal panels of miRNA pairs, capable of diagnosing NSCLC with 100% accuracy: (1) -19b/-425, -125b/-378a, -205/-660; (2) -324/-374a, -30e/-92a, -125b/-378a; (3) -324/-374a, -125b/-378a, -205/-660. CONCLUSION: The diagnostic performance of the proposed miRNA panel across independent cohorts, along with the observed inter-cohort variability, supports its promising potential for NSCLC screening test development. These data demonstrate the necessity to identify additional multi-purpose miRNA markers and to validate the panel in further independent patient groups. Such research is essential to establish a reliable and timely miRNA-based screening tool for NSCLC.
- Open Access
- 15 May 2023
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 10 (2) , 78-89
Cell-free plasma miRNAs analysis for low invasive lung cancer diagnostics
Introduction. The high mortality rate in patients with lung cancer (LC) is due to the lack of highly sensitive diagnostic markers of this disease. Genetic and epigenetic alterations in tumor cells, for example, aberrant microRNA expression, can be proposed. It is known that extracellular/circulating microRNA of biological fluids, in complexes with proteins, or packaged in extracellular vesicles is of interest for the diagnosis of tumor diseases.Aim. To perform a comparative analysis of miRNA expression in plasma and plasma extracellular vesicles of LC patients and healthy donors. Based on the obtained results, to propose a diagnostic panel to identify patients with LC.Materials and methods. Blood plasma was obtained from blood samples of healthy donors and LC patients by sequential centrifugation. Then, a fraction of extracellular vesicles (40–150 nm in size) was isolated from a part of the obtained plasma supernatant by the method of aggregation-precipitation with polyethylene glycol/blue dextran. MicroRNAs were isolated from both blood plasma fractions of patients and healthy donors using guanidine isothiocyanate and octanoic acid. Expression of 17 miRNAs most characteristic for the development of LC according to our and literature data in the above-mentioned blood plasma fractions was analyzed by stem-loop reverse transcription polymerase chain reaction.Results. 29 and 10 miRNA pairs were differentially expressed in plasma extracellular vesicles and plasma of lung cancer patients and donors. Thus, plasma extracellular vesicles are characterized by greater potential as a source for miRNA based lung cancer diagnostic panels in comparison with blood plasma. Diagnostic algorithm based on aberrant miRNA expression of 8 different miRNAs (miRNA-30e, -1, -125b, -133, -222, -374, -425, -660) composed in 6 pairs was designed. This algorithm allows to diagnose 100 % of patients with lung cancer stages II–IV.Conclusion. Extracellular plasma vesicles represent a promising source of diagnostically significant microRNAs compared to plasma microRNAs. For the diagnosis of patients with non-small cell lung cancer with 100 % sensitivity and specificity, a panel of 8 microRNAs (6 miRNA pairs) was proposed.
- 15 May 2023
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 10 (2) , 78-89
Open AccessCell-free plasma miRNAs analysis for low invasive lung cancer diagnostics
Introduction. The high mortality rate in patients with lung cancer (LC) is due to the lack of highly sensitive diagnostic markers of this disease. Genetic and epigenetic alterations in tumor cells, for example, aberrant microRNA expression, can be proposed. It is known that extracellular/circulating microRNA of biological fluids, in complexes with proteins, or packaged in extracellular vesicles is of interest for the diagnosis of tumor diseases.Aim. To perform a comparative analysis of miRNA expression in plasma and plasma extracellular vesicles of LC patients and healthy donors. Based on the obtained results, to propose a diagnostic panel to identify patients with LC.Materials and methods. Blood plasma was obtained from blood samples of healthy donors and LC patients by sequential centrifugation. Then, a fraction of extracellular vesicles (40–150 nm in size) was isolated from a part of the obtained plasma supernatant by the method of aggregation-precipitation with polyethylene glycol/blue dextran. MicroRNAs were isolated from both blood plasma fractions of patients and healthy donors using guanidine isothiocyanate and octanoic acid. Expression of 17 miRNAs most characteristic for the development of LC according to our and literature data in the above-mentioned blood plasma fractions was analyzed by stem-loop reverse transcription polymerase chain reaction.Results. 29 and 10 miRNA pairs were differentially expressed in plasma extracellular vesicles and plasma of lung cancer patients and donors. Thus, plasma extracellular vesicles are characterized by greater potential as a source for miRNA based lung cancer diagnostic panels in comparison with blood plasma. Diagnostic algorithm based on aberrant miRNA expression of 8 different miRNAs (miRNA-30e, -1, -125b, -133, -222, -374, -425, -660) composed in 6 pairs was designed. This algorithm allows to diagnose 100 % of patients with lung cancer stages II–IV.Conclusion. Extracellular plasma vesicles represent a promising source of diagnostically significant microRNAs compared to plasma microRNAs. For the diagnosis of patients with non-small cell lung cancer with 100 % sensitivity and specificity, a panel of 8 microRNAs (6 miRNA pairs) was proposed.